USA flag logo/image

An Official Website of the United States Government

Amplifying mRNAs for Bacterial Array Analysis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65991
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI051920
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMBION DIAGNOSTICS, INC.
Asuragen, Inc. 2150 WOODWARD ST AUSTIN, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Amplifying mRNAs for Bacterial Array Analysis
Agency: HHS
Contract: 2R44AI051920-02
Award Amount: $787,035.00
 

Abstract:

DESCRIPTION (provided by applicant): In the past several years, a significant need has arisen to analyze bacterial gene expression following interactions with host cells in vivo. In vivo whole genome expression analyses are seen as crucial for identifying novel bacterial targets for therapeutic intervention and for a comprehensive understanding of bacterial pathogenesis. This work will develop, improve, optimize, and validate methods for (1) the purification of bacterial mRNAs from complex mixtures of host cell and bacterial RNA and (2) the global amplification of bacterial mRNAs following their purification from complex RNA mixtures. The goals of this study are to maximize recovery and amplification of bacterial mRNAs while maintaining accurate gene representation in the final sample. Methods and procedures will be validated by microarray expression analysis studies. Optimized procedures will be incorporated into first- and second-generation kits that will comprise complete systems for the purification and amplification of bacterial mRNAs from in vitro and in vivo samples containing excessive amounts of eukaryotic host cell RNA. Results of the work performed here will enable scientists to capitalize on NIH investments in bacterial genome sequencing - by performing extensive analyses of bacterial gene expression during the host phase of the bacterial life cycle. These newly enable studies will assist in identifying genes and gene products important for initiating bacterial infections, for enabling bacterial replication within the host, and for evasion of host immune responses. Gene expression analyses with non-cultivable pathogens, insect-borne pathogens, and commensal organisms will also be enabled. With the technology developed here, new basic research will be focused on identifying novel vaccine candidates and expanding the number of potential targets for therapeutic intervention.

Principal Investigator:

Robert A. Setterquist
5126510200
BSETTERQUIST@AMBION.COM

Business Contact:

Rigo Vallejo
5126510200
RVALLEJO@AMBION.COM
Small Business Information at Submission:

AMBION, INC.
2130 WOODWARD STREET AUSTIN, TX 78744

EIN/Tax ID: 742515119
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No